The Egyptian Company for Medical Investments (ECMI) serves as the holding arm for the UPA’s commercial subsidiaries. Its strategic role involves the efficient management of import, distribution, and commercial operations for medical and pharmaceutical supplies. ECMI is focused on ensuring compliance with international quality standards, maintaining real-time inventory visibility, and leveraging consolidated data to support strategic decision-making and enhance operational efficiency across the group.
Established in 1965, Egydrug is a cornerstone of the national distribution system. It holds the pivotal responsibility for the trade and distribution of pharmaceutical products nationwide. Egydrug is a major national importer and distributor, specifically tasked with securing the supply of essential imported medicines—including oncology and biotechnological products—that lack local alternatives. Furthermore, the company ensures the maintenance of strategic reserves for critical items such as infant formula and insulin, acting as a crucial safety valve for the Egyptian citizen.
Gonco is the specialized trading entity for a wide range of chemicals, medical equipment, and supplies. It plays a significant operational role in handling comprehensive procurement tenders that cover the diverse needs of the governmental health sector, including health insurance bodies and public hospitals. Gonco is also mandated to support state-funded treatment programs by supplying specialized medical aids, such as hearing devices, walking assistance devices, and prosthetics, ensuring citizens receive necessary therapeutic support with a focus on quality and timely delivery.
The Strategic Stores Company is a joint venture that includes the UPA, Egypt’s Sovereign Fund (Misr Fund), and the Armed Forces Land Projects Agency. This partnership is establishing a modern, high-capacity logistics infrastructure across six governorates. The company's mandate is to provide state-of-the-art warehousing and distribution capabilities, ensuring the reliable and rapid movement of medical products. This project is a crucial component of the national strategy to maintain large-scale strategic reserves, thereby enhancing the country's capability to withstand supply shocks and support the competitiveness of Egyptian medical products for export.
GMS represents a strategic public-private partnership between ECMI (representing UPA), Interpharm, and the global leader, JMS Japan. This venture is dedicated to establishing a state-of-the-art manufacturing facility for the local production of blood bags and their components in the Suez Canal Economic Zone. The core objective is to achieve 100% self-sufficiency in meeting Egypt’s annual demand for blood bags, coupled with a robust export program, thereby fulfilling the national strategy for technology transfer and localization of critical medical industries.
Need help? Our team is just a message away